Clinical Trial Update: A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and effectiveness of canagliflozin for weight loss in overweight and obese adults without diabetes; results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Canagliflozin (canagliflozin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Obesity | Phase 2 | Status: COMPLETED | Results posted: 2013-05-24